Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.
Business Model:
Revenue: $5.7M
Employees: 2-10
Address: 2882 Sand Hill Road Suite 121
City: Menlo Park
State: CA
Zip: 94025
Country: US
AVM is a venture capital firm focusing on human therapeutics field.
Contact Phone:
+16504946000
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2021 | NeoPhore | Series B | 0 |
12/2014 | Crescendo Biologics | Venture Round | - |
9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
8/2008 | F2G | Venture Round | 11.8M |
1/2011 | PanOptica | Series A | 30M |
7/2009 | Viamet Pharmaceuticals | Series B | 25M |
10/2009 | Evolva | Series B | 27.8M |
10/2014 | Viamet Pharma | Series D | 60M |
6/2022 | Carbon Biosciences | Series A | 0 |
2/2021 | Orna Therapeutics | Series A | 0 |
9/2020 | Fukushima SiC Applied Engineering | Series C | 0 |
6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
8/2020 | Trishula Therapeutics | Funding Round | - |
12/2013 | Crescendo Biologics | Series A | 28.5M |
8/2007 | Nereus Pharmaceuticals | Series D | 0 |
9/2010 | DecImmune Therapeutics | Venture Round | 3.2M |
12/2016 | Trieza Therapeutics | Pre Seed Round | - |
6/2008 | Inimex Pharmaceuticals | Series B | 22M |
4/2022 | Turn.bio | Venture Round | - |
1/2023 | NeoPhore | Series B | 0 |
8/2016 | Cleave Therapeutics | Series B | 0 |
11/2011 | Cleave Therapeutics | Series A | 42M |
8/2019 | Cleave Therapeutics | Series C | 0 |
5/2013 | Effector Therapeutics | Series A | 45M |
11/2019 | Heartseed | Series B | 0 |
6/2010 | Nereus Pharmaceuticals | Series E | 0 |
7/2011 | Verastem Oncology | Series B | 32M |
5/2021 | Mogrify | Series A | 0 |
4/2014 | Crescendo Biologics | Series A | 3.3M |
12/2012 | Bicycle Therapeutics | Venture Round | 6M |
11/2022 | Casma Therapeutics | Series C | 46M |
3/2021 | PhoreMost | Series B | 45.3M |
10/2014 | Bicycle Therapeutics | Series A | 32M |
1/2009 | Intradigm Corporation | Series B | 0 |
10/2014 | Raze Therapeutics | Series A | 24M |
11/2020 | Catamaran Bio | Series A | 0 |
11/2009 | Fate Therapeutics | Series B | 30M |
11/2019 | CODA Biotherapeutics | Series A | 15M |
1/2016 | Tizona Therapeutics | Series A | 27M |
10/2009 | Epizyme | Series B | 32M |
5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
12/2015 | Effector Therapeutics | Series B | 40M |
2/2006 | Lectus Therapeutics | Series A | 14.3M |
6/2022 | DEM BioPharma | Series A | 0 |
7/2017 | Effector Therapeutics | Series C | 38.6M |
8/2019 | Oncorus | Series B | 0 |
12/2016 | Oncorus | Series A | 5M |
9/2012 | F2G | Equity | 30M |
9/2018 | CODA Biotherapeutics | Series A | 19M |
5/2011 | Fate Therapeutics | Series B | 36M |
2/2023 | Avilar Therapeutics | Seed Round | 0 |
7/2018 | Heartseed | Series A | 7.2M |
2/2013 | DecImmune Therapeutics | Venture Round | 2.3M |
1/2020 | TScan Therapeutics | Series B | 35M |
3/2016 | Tizona Therapeutics | Series B | 43M |
9/2006 | CoMentis | Series B | 50M |
3/2006 | F2G | Venture Round | 8.7M |
6/2022 | DEM BioPharma | Series A | 0 |
6/2022 | Carbon Biosciences | Series A | 0 |
4/2022 | Turn.bio | Venture Round | - |
5/2021 | Mogrify | Series A | 0 |
3/2021 | PhoreMost | Series B | 0 |
3/2021 | NeoPhore | Series B | 0 |
2/2021 | Orna Therapeutics | Series A | 0 |
11/2020 | Catamaran Bio | Series A | 0 |
9/2020 | Fukushima SiC Applied Engineering | Series C | 0 |
8/2020 | Trishula Therapeutics | Funding Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|